147 related articles for article (PubMed ID: 35359599)
1. KRAS Mutation in Rare Tumors: A Landscape Analysis of 3453 Chinese Patients.
Wang S; Li Q; Ma P; Fang Y; Yu Y; Jiang N; Miao H; Tang Q; Yang Y; Xing S; Chen R; Yi X; Li N
Front Mol Biosci; 2022; 9():831382. PubMed ID: 35359599
[TBL] [Abstract][Full Text] [Related]
2. Landscape of
Salem ME; El-Refai SM; Sha W; Puccini A; Grothey A; George TJ; Hwang JJ; O'Neil B; Barrett AS; Kadakia KC; Musselwhite LW; Raghavan D; Van Cutsem E; Tabernero J; Tie J
JCO Precis Oncol; 2022 Mar; 6():e2100245. PubMed ID: 35319967
[TBL] [Abstract][Full Text] [Related]
3. Extensive genomic analysis in patients with
Jacobsen IC; Spanggaard I; Højgaard M; Belcaid L; Qvortrup C; Yde CW; Schmidt AY; Nielsen FC; Willemoe GL; Dam MS; Lassen U; Staal Rohrberg K
Acta Oncol; 2022 Dec; 61(12):1499-1506. PubMed ID: 36529989
[TBL] [Abstract][Full Text] [Related]
4. KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples.
Loong HH; Du N; Cheng C; Lin H; Guo J; Lin G; Li M; Jiang T; Shi Z; Cui Y; Jin X; Yao J; Xing Y; Yao M; Wang K; Mok TSK; Liu L
Transl Lung Cancer Res; 2020 Oct; 9(5):1759-1769. PubMed ID: 33209599
[TBL] [Abstract][Full Text] [Related]
5. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma.
Tao L; Miao R; Mekhail T; Sun J; Meng L; Fang C; Guan J; Jain A; Du Y; Allen A; Rzeszutko BL; Socinski MA; Chang CC
Clin Lung Cancer; 2021 Jul; 22(4):e506-e511. PubMed ID: 32807653
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors.
Lee JK; Sivakumar S; Schrock AB; Madison R; Fabrizio D; Gjoerup O; Ross JS; Frampton GM; Napalkov P; Montesion M; Schutzman JL; Ye X; Hegde PS; Nagasaka M; Oxnard GR; Sokol ES; Ou SI; Shi Z
NPJ Precis Oncol; 2022 Dec; 6(1):91. PubMed ID: 36494601
[TBL] [Abstract][Full Text] [Related]
8. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.
Araujo LH; Souza BM; Leite LR; Parma SAF; Lopes NP; Malta FSV; Freire MCM
BMC Cancer; 2021 Feb; 21(1):193. PubMed ID: 33632153
[TBL] [Abstract][Full Text] [Related]
9. Landscape of RAS Variations in 17,993 Pan-cancer Patients Identified by Next-generation Sequencing.
Zhou S; Zhang D; Li J; Zhao J; Wang G; Zhang Y; Bai Y; Chen D; Wu H
Pathol Oncol Res; 2020 Oct; 26(4):2835-2837. PubMed ID: 32602003
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With
Wu SG; Liao WY; Su KY; Yu SL; Huang YL; Yu CJ; Chih-Hsin Yang J; Shih JY
JTO Clin Res Rep; 2021 Feb; 2(2):100140. PubMed ID: 34589991
[TBL] [Abstract][Full Text] [Related]
11. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.
Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Genomic Profiling of Rare Tumors in China: Routes to Immunotherapy.
Wang S; Fang Y; Jiang N; Xing S; Li Q; Chen R; Yi X; Zhang Z; Li N
Front Immunol; 2021; 12():631483. PubMed ID: 33732253
[TBL] [Abstract][Full Text] [Related]
13. Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy.
Cefalì M; Epistolio S; Ramelli G; Mangan D; Molinari F; Martin V; Freguia S; Mazzucchelli L; Froesch P; Frattini M; Wannesson L
J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329953
[TBL] [Abstract][Full Text] [Related]
14. A Real-World Study in Advanced Non-Small Cell Lung Cancer with KRAS Mutations.
Lei L; Wang WX; Yu ZY; Liang XB; Pan WW; Chen HF; Wang LP; Fang Y; Wang M; Xu CW; Fang MY
Transl Oncol; 2020 Feb; 13(2):329-335. PubMed ID: 31881505
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a cohort of metastatic lung cancer patients harboring
Notario L; Cucurull M; Cerdà G; Sanz C; Carcereny E; Muñoz-Mármol A; Hernández A; Domènech M; Morán T; Sánchez-Céspedes M; Costa M; Mate JL; Esteve A; Saigí M
Front Oncol; 2023; 13():1239000. PubMed ID: 37916173
[TBL] [Abstract][Full Text] [Related]
16. The relationship between different subtypes of
Yang Y; Shen S; Sun Y; Husain H; Zhou H; Lu S; Li Z
Transl Lung Cancer Res; 2022 Feb; 11(2):213-223. PubMed ID: 35280306
[TBL] [Abstract][Full Text] [Related]
17. Increased KRAS G12C Prevalence, High Tumor Mutational Burden, and Specific Mutational Signatures Are Associated With MUTYH Mutations: A Pan-Cancer Analysis.
Disel U; Sivakumar S; Pham T; Fleischmann Z; Anu RI; Sokol ES; Kurzrock R
Oncologist; 2024 Feb; 29(2):e213-e223. PubMed ID: 37589222
[TBL] [Abstract][Full Text] [Related]
18. A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.
Kartolo A; Feilotter H; Hopman W; Fung AS; Robinson A
Cancer Treat Res Commun; 2021; 27():100330. PubMed ID: 33581492
[TBL] [Abstract][Full Text] [Related]
19. Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
Zhao D; Li H; Mambetsariev I; Mirzapoiazova T; Chen C; Fricke J; Kulkarni P; Villaflor V; Arvanitis L; Hamilton S; Afkhami M; Pillai R; Armstrong B; Erhunmwunsee L; Massarelli E; Sattler M; Amini A; Salgia R
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230855
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
